These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 10224383)
21. The current state of recombinant allergens for immunotherapy. Pauli G; Malling HJ Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):575-81. PubMed ID: 20859201 [TBL] [Abstract][Full Text] [Related]
22. Recombinant expression, purification and cross-reactivity of chenopod profilin: rChe a 2 as a good marker for profilin sensitization. Barderas R; Villalba M; Rodríguez R Biol Chem; 2004 Aug; 385(8):731-7. PubMed ID: 15449709 [TBL] [Abstract][Full Text] [Related]
27. cDNA cloning and expression of timothy grass (Phleum pratense) pollen profilin in Escherichia coli: comparison with birch pollen profilin. Valenta R; Ball T; Vrtala S; Duchêne M; Kraft D; Scheiner O Biochem Biophys Res Commun; 1994 Feb; 199(1):106-18. PubMed ID: 8123000 [TBL] [Abstract][Full Text] [Related]
28. Pollen and plant food profilin allergens show equivalent IgE reactivity. Sirvent S; Tordesillas L; Villalba M; Díaz-Perales A; Cuesta-Herranz J; Salcedo G; Rodríguez R Ann Allergy Asthma Immunol; 2011 May; 106(5):429-35. PubMed ID: 21530876 [TBL] [Abstract][Full Text] [Related]
29. Identification of a villin-related tobacco protein as a novel cross-reactive plant allergen. Mittermann I; Voronin V; Heberle-Bors E; Valenta R FEBS Lett; 2005 Jul; 579(17):3807-13. PubMed ID: 15978584 [TBL] [Abstract][Full Text] [Related]
30. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688 [TBL] [Abstract][Full Text] [Related]
31. Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening. Thalhamer T; Dobias H; Stepanoska T; Pröll M; Stutz H; Dissertori O; Lackner P; Ferreira F; Wallner M; Thalhamer J; Hartl A J Allergy Clin Immunol; 2010 Apr; 125(4):926-934.e10. PubMed ID: 20371399 [TBL] [Abstract][Full Text] [Related]
32. Cross-reactivity of pollen allergens: impact on allergen immunotherapy. Weber RW Ann Allergy Asthma Immunol; 2007 Sep; 99(3):203-11; quiz 212-3, 231. PubMed ID: 17910323 [TBL] [Abstract][Full Text] [Related]
33. Monovalent fusion proteins of IgE mimotopes are safe for therapy of type I allergy. Ganglberger E; Barbara Sponer ; Schöll I; Wiedermann U; Baumann S; Hafner C; Breiteneder H; Suter M; Boltz-Nitulescu G; Scheiner O; Jensen-Jarolim E FASEB J; 2001 Nov; 15(13):2524-6. PubMed ID: 11641259 [TBL] [Abstract][Full Text] [Related]
34. Clinically relevant peach allergy is related to peach lipid transfer protein, Pru p 3, in the Spanish population. Fernández-Rivas M; González-Mancebo E; Rodríguez-Pérez R; Benito C; Sánchez-Monge R; Salcedo G; Alonso MD; Rosado A; Tejedor MA; Vila C; Casas ML J Allergy Clin Immunol; 2003 Oct; 112(4):789-95. PubMed ID: 14564363 [TBL] [Abstract][Full Text] [Related]
35. Genetic engineering of allergens: future therapeutic products. Ferreira F; Wallner M; Breiteneder H; Hartl A; Thalhamer J; Ebner C Int Arch Allergy Immunol; 2002 Jul; 128(3):171-8. PubMed ID: 12119498 [TBL] [Abstract][Full Text] [Related]
36. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4. Shirasaki H; Yamamoto T; Koyanagi Y; Watanabe N; Himi T Allergol Int; 2008 Mar; 57(1):93-6. PubMed ID: 18209509 [TBL] [Abstract][Full Text] [Related]
37. Recombinant allergens for specific immunotherapy. Valenta R; Vrtala S Allergy; 1999; 54 Suppl 56():43-4. PubMed ID: 10532305 [No Abstract] [Full Text] [Related]
38. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis. Rossi RE; Monasterolo G; Coco G; Operti D Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987 [TBL] [Abstract][Full Text] [Related]
39. The impact of molecular biology on allergen immunotherapy. Bush RK Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):557-8. PubMed ID: 21030836 [No Abstract] [Full Text] [Related]
40. Recombinant allergens for pollen immunotherapy. Wallner M; Pichler U; Ferreira F Immunotherapy; 2013 Dec; 5(12):1323-38. PubMed ID: 24283843 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]